View all news

SQZ Biotechnologies to Present at Upcoming Investor Conferences

09/07/2022

WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder at SQZ Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 and at the Chardan 6th Annual Genetic Medicines Conference on October 4. Both conference presentations will be held in New York, NY. Presentation times and webcast information are available below.

PRESENTATION DETAILS

Wednesday, September 14
H.C. Wainwright 24th Annual Global Investment Conference
11:00-11:30 a.m. ET
Webcast

Tuesday, October 4
Chardan 6th Annual Genetic Medicines Conference
1:30-2:00 p.m. ET
Webcast

Conference webcast details and the company’s most recent corporate overview presentation will be available on the Investors section of the SQZ website. Replays will be available for 60 days.

Based on guidance from the SEC, investors should note that the company may announce future healthcare conference presentations on the Events & Presentations page within the Investor Relations section of its corporate website, investors.sqzbiotech.com. It is possible that the information posted there could be deemed to be material information.

About SQZ Biotechnologies
SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could change the way people think about cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and in immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases. For more information, please visit www.sqzbiotech.com.

Investor Contact:
Mike Kaiser
857-760-0398
michael.kaiser@sqzbiotech.com

Media Contact:
Erin Phelps
857-760-0920
erin.phelps@sqzbiotech.com

Source: SQZ Biotechnologies Company

Multimedia Files:

View all news